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BACKGROUND: Several colorectal cancer-screening tests are available, but it is uncertain which provides the best balance of risks and
benefits within a screening programme. We evaluated cost-effectiveness of a population-based screening programme in Ireland based
on (i) biennial guaiac-based faecal occult blood testing (gFOBT) at ages 55–74, with reflex faecal immunochemical testing (FIT);
(ii) biennial FIT at ages 55–74; and (iii) once-only flexible sigmoidoscopy (FSIG) at age 60.
METHODS: A state-transition model was used to estimate costs and outcomes for each screening scenario vs no screening. A third
party payer perspective was adopted. Probabilistic sensitivity analyses were undertaken.
RESULTS: All scenarios would be considered highly cost-effective compared with no screening. The lowest incremental cost-
effectiveness ratio (ICER vs no screening h589 per quality-adjusted life-year (QALY) gained) was found for FSIG, followed by FIT
(h1696) and gFOBT (h4428); gFOBT was dominated. Compared with FSIG, FIT was associated with greater gains in QALYs and
reductions in lifetime cancer incidence and mortality, but was more costly, required considerably more colonoscopies and resulted in
more complications. Results were robust to variations in parameter estimates.
CONCLUSION: Population-based screening based on FIT is expected to result in greater health gains than a policy of gFOBT (with reflex
FIT) or once-only FSIG, but would require significantly more colonoscopy resources and result in more individuals experiencing
adverse effects. Weighing these advantages and disadvantages presents a considerable challenge to policy makers.
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In 2008, an estimated 1.2 million new cases of colorectal cancer
were diagnosed worldwide and 600 000 people died from the
disease (Ferlay et al, 2010). It is the third most common cancer in
men and second most common in women. In light of this burden,
various international organisations have strongly recommended
implementation of colorectal cancer screening (Council of the
European Union, 2003; US Preventive Services Task Force, 2008).
Several screening tests are available which, by detecting benign
adenomas or early cancers, might reduce colorectal cancer
mortality and, potentially, incidence in the population. Until
recently, the only test for which there was robust evidence of
efficacy from randomised controlled trials (RCTs) was the guaiac-
based faecal occult blood test (gFOBT). Repeated screening with
gFOBT results in a 16% mortality reduction (Hewitson et al, 2007),
evidence which underpinned the decision to base the UK colorectal
cancer-screening programmes on gFOBT. However, gFOBTs have
several weaknesses, including limited sensitivity even when used
biennially (Burch et al, 2007; van Dam et al, 2010). In addition,
substantial proportions of screened individuals need to complete
a second (reflex) test before a decision is taken on referral for
diagnostic investigation by colonoscopy. Recent years have seen
the development of faecal immunochemical tests (FIT), which are
specific for bleeding of colorectal origin and do not require
individuals to undergo dietary restrictions (van Dam et al, 2010).
Although evidence is lacking on whether FIT-based screening is
effective in reducing mortality, RCTs show that these tests have a
higher neoplasia detection rate and positive predictive value than
gFOBTs (van Rossum et al, 2008; Hol et al, 2010; Levi et al, 2011).
In addition, some studies show a higher uptake with FIT (Cole and
Young, 2001; Deutekom et al, 2010; Hol et al, 2010). On this basis,
FIT is now considered an acceptable screening option by various
bodies (Levin et al, 2008). However, compared with gFOBT, FIT
kits are generally more expensive and (older) qualitative FITs have
a lower analytical detection limit, resulting in a high colonoscopy
referral rate (Fraser et al, 2007), both key considerations for
publicly funded screening programmes. Newer quantitative FITs
allow the cut-off to define a ‘positive’ result to be varied (Hol et al,
2009), which provides a potentially attractive way to control
colonoscopy requirements. A different way of managing the
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challenge of colonoscopy referrals has been adopted in the
screening programme in Scotland, where FIT is used for reflex
testing following a positive gFOBT. This has reduced the
proportion of screened individuals referred for colonoscopy
compared with using second-line gFOBT (Fraser et al, 2006,
2007). However, the potential impact of gFOBT with reflex FIT on
cancer incidence and mortality does not appear to have been
evaluated.
An alternative approach to screening is to use an endoscopy-
based test. This option is firmly back on the agenda following
publication of results from three RCTs (Hoff et al, 2009;
Atkin et al, 2010; Segnan et al, 2011). In two trials, a single
examination between age 55 and 64 was associated with signi-
ficant reductions in colorectal cancer incidence and/or mortality
(Atkin et al, 2010; Segnan et al, 2011) whereas in the other,
although incidence was not reduced in those randomised to
screening, a non-significant decrease in mortality was observed
(Hoff et al, 2009).
Cost-effectiveness analysis provides a methodology for compar-
ing the costs and benefits of alternative healthcare interventions.
Evaluations of cost-effectiveness of colorectal cancer screening
have been conducted in several countries (HIQA, 2009; Landsdorp-
Vogelaar et al, 2010, and references therein). Most suggest that
screening – by one of a range of different tests and strategies – is
likely to be considered cost-effective compared with no screening.
However, uncertainty remains. None of the screening tests appear
optimal across all settings (Lansddorp-Vogelaar et al, 2010) and it
is unclear which of the current options are likely to provide the
best balance of costs and benefits. In particular, the evidence based
around FIT is limited (Berchi et al, 2010; Telford et al, 2010;
Lejeune et al, 2010; Hassan et al, 2011; van Rossum et al, 2011),
and it does not appear to have been evaluated alongside once-only
flexible sigmoidoscopy (FSIG). The aim of this study was to
estimate the incremental cost-effectiveness of a population-based
colorectal cancer-screening programme using primary FIT, gFOBT
with reflex FIT testing, or once-only FSIG compared with no
screening.
MATERIALS AND METHODS
Setting and screening scenarios
The study setting was Ireland. Ireland has a mixed public-private
health care system, but population-based cancer screening
programmes are provided free at the point of delivery. Three
primary screening scenarios were evaluated: (1) biennial gFOBT,
with reflex FIT, in those aged 55–74 years; (2) biennial FIT in
those aged 55–74 years; and (3) once-only FSIG at age 60. In
secondary analyses, five age-variant scenarios were considered:
(1) biennial gFOBT, with reflex FIT, at 55–64 years; (2) biennial
gFOBT, with reflex FIT, at 65–74 years; (3) biennial FIT at 55–64
years; (4) biennial FIT at 65–74 years; and (5) once-only FSIG at
age 55. This evaluation was conducted to inform health policy and
decision-making in Ireland, and the screening scenarios were
determined largely by an Expert Group established to oversee the
evaluation. It was assumed that investigation of positive screening
tests would be by colonoscopy, with CT colonography in those
unfit for colonoscopy, or in whom colonoscopy was incomplete.
Follow-up of individuals who had adenomas detected and removed
was assumed to follow existing guidelines (Atkin and Saunders,
2002). Briefly, those who had low-risk adenomas removed would
return to routine screening and those who had intermediate or
high-risk adenomas removed would enter ongoing colposcopic
surveillance, conducted annually for those with high-risk findings
and every 3 years for those with intermediate-risk findings.
Individuals would exit surveillance after two clear tests 3 years
apart.
Economic model structure
The economic model was a state transition (Markov process) model
with three interlinked components relating to the: (1) natural history
of colorectal neoplasia; (2) impact of screening and subsequent
adenoma surveillance; and (3) impact of mortality.
The natural history model simulated the experience of a cohort of
individuals over their lifetime through health states relating to the
progression from normal colorectal epithelium, through the
adenoma-carcinoma sequence, to death (Figure 1). During each
annual Markov cycle the model cohort was distributed across the
health states, with these transitions governed by a series of
transition matrices (probabilities). Health states were defined in
terms of an ‘index’ lesion, that is the greatest malignant potential of
the adenoma(s) present, or most advanced cancer present.
Individuals with adenomas were classified as low-risk (o10mm)
or higher-risk (X10mm), with the latter category broadly
corresponding to the combination of intermediate- and high-risk
described by Atkin and Saunders, 2002. Intermediate- and high-risk
were not modelled separately owing to limitations in the evidence
relating to progression rates through low-intermediate-high risk
(Tappenden et al, 2004). Discrete cancer states were modelled
individually according to AJCC staging. Adenomatous polyps and
cancers located in the distal and proximal colon were considered
separately to account for the reach of FSIG, with some correlation
implicitly modelled by assuming 70% arose in the distal, and 30%
in the proximal, colon. Fourteen percent of cancers (based on
Munkholm, 2003; Makinen, 2007) were assumed to develop without
a prior adenoma (i.e. in individuals with inflammatory bowel
disease, or flat or serrated adenomas) and modelled as direct
progression from normal epithelium to stage I cancer.
The screening intervention model was superimposed upon
the natural history model. The characteristics of the screen-
ing (gFOBT, FIT, and FSIG) and diagnostic (colonography,
CT colonography) tests were defined in terms of true sensitivity
and specificity. The impact of the screening and diagnostic tests,
and clinical management of adenomas and cancers, was modelled
by redistributing the cohort across the health states at the point
of screening or surveillance. Individuals in whom adenomas
were detected were assumed to undergo polypectomy and enter
surveillance, as described above. Individuals in whom cancer
was detected entered a stage-specific clinical management state.
Individuals in whom neither cancer nor adenoma was detected
were re-invited for screening in the next round, if applicable.
Owing to a lack of data, the model assumed that performance
characteristics of gFOBT and reflex FIT were independent, and that
everyone who had a positive gFOBT completed a reflex FIT.
The mortality model allowed for deaths because of colorectal
cancer, endoscopic bowel perforation, or other causes. The probability
Stage IV CRC
NORMAL Low-risk
adenoma(s)
Intermediate/high-
risk adenoma(s)
Stage I CRC Stage II CRC Stage III CRC
DEATH
DEATH
Figure 1 Simplified schematic of natural history model states and
transitions. Low-risk adenoma: o10mm; intermediate/high-risk adenomas:
X10mm; Abbreviation: CRC¼ colorectal cancer.
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of dying from other causes was based on Irish life tables and
modelled as an age-dependent probability during each Markov
cycle. The risk of death from endoscopic perforation was applied
during screening (FSIG only), diagnostic investigation, and adenoma
surveillance. The probability of dying from colorectal cancer was
assumed to be higher for more advanced disease.
The cohort entered the simulation at age 30, at which point it
was assumed that prevalence of pre-clinical cancers and adenomas
was zero, which is likely to be reasonable for cancers that arise
in individuals without specific genetic syndromes (‘sporadic’
cancers). Thus, the prevalence of disease accumulated over the
pre-screening period (30–54 or 30–59). The simulation ended at
age 100, by which time almost all members were absorbed into the
‘death’ health state.
Model parameters and calibration
Model parameters were determined from comprehensive lite-
rature reviews (published papers supplemented by data from
ongoing population-based screening programmes, pilot pro-
grammes, and RCTs) and expert opinion if no relevant data
was available. For each parameter, we identified a base-case
value and range and distribution for use in sensitivity analyses
(Table 1).
Estimates of screening uptake, and colonoscopy compliance,
were based on the UK pilot programmes and FSIG trial (UK
Flexible Sigmoidoscopy Screening Trial Investigators, 2002; Weller
et al, 2006; Information Services Division, 2008) with various other
studies informing the range for sensitivity analyses. Sensitivity and
specificity of gFOBT and FIT were derived from pooled analysis of
information from diagnostic cohort studies (i.e. the diagnosis had
not been determined prior to recruitment, and all participants
underwent the index test and reference standard test), which
included ‘screening populations’ and, for gFOBT, which used
Hemoccult (Beckman Coulter, Inc., Brea, CA, USA) or Hemoccult
II (Allison et al, 1990, 1996, 2007; Castiglione et al, 1991; Foley
et al, 1992; Itoh et al, 1996; Brevinge et al, 1997; Chen et al, 1997;
Nakama et al, 2000, 2001; Lieberman and Weiss, 2001; Cheng et al,
2002; Niv et al, 2002; Gondal et al, 2003; Liu et al, 2003; Sung et al,
2003; Collins et al, 2005; Morikawa et al, 2005, 2007; Nakazato et al,
2006). Three studies were combined to estimate sensitivity of FSIG
for intermediate/high-risk adenomas (Rozen et al, 1987, Lieber-
man and Weiss, 2001; Sung et al, 2003). As studies included few (if
any) low-risk adenomas or cancers, sensitivity estimates for these
parameters were based on expert clinical opinion, assuming the
former would be lower than for intermediate/high-risk lesions
and the latter higher. Specificity was also based on expert opinion.
Colonoscopy sensitivity was based on ‘miss rates’ from studies
of individuals who underwent tandem colonoscopies (van Rijn
et al, 2006; Bressler et al, 2007), augmented by expert opinion
for specificity. CT colonoscopy performance characteristics were
from expert opinion informed by reviews and large-scale studies
(Cotton et al, 2004; Halligan et al, 2005; Mulhall et al, 2005;
Johnson et al, 2008).
A healthcare payer perspective was adopted, in this case the
Health Service Executive (HSE). Direct costs, in h2008 values,
associated with screening and cancer management were included.
Costs of gFOBT and FIT kits and associated processing were
estimated following discussion with the National Cancer Screening
Service, test suppliers, and laboratory staff, and using Department
of Health and Children salary scales. The cost of FSIG was
estimated from a UK audit (Whynes et al, 2003; converted to Euros
and inflated using the consumer price index for health) and Irish
private health insurer fee schedules. Diagnostic-related group
(DRG) costs (HSE Casemix Unit, 2008) were the source for
colonoscopy costs. The cost of CT colonography was estimated
from expert opinion informed by the fee paid by the HSE for a
patient undergoing the procedure in a private facility. Estimation
of stage-specific costs of treating (a) screen-detected and (b)
symptomatic colorectal cancers is described in detail elsewhere
(Tilson et al, 2011).
The probability of perforation with FSIG was derived from the UK
FSIG Trial (UK Flexible Sigmoidoscopy Screening Trial Investiga-
tors, 2002). For colonoscopy, audit data was used to derive estimates
for perforation with and without polypectomy (Dafnis et al, 2001).
The probability of death following perforation came from Gatto et al
(2003). The UK FSIG Trial informed estimates of episodes of major
bleeding following FSIG and colonoscopy (UK Flexible Sigmoido-
scopy Screening Trial Investigators, 2002). The costs of treating a
bowel perforation and managing a major bleed (which was assumed
to result in hospital admission) were estimated from DRG costs
(HSE Casemix Unit, 2008).
Health outcomes were measured as quality-adjusted life years
(QALYs). Utility for cancer-free individuals was obtained from
Fryback and Lawrence (1997) and colorectal cancer stage-specific
utility estimates from Ramsey et al (2000).
Some model parameters, including the natural history transition
probabilities, could not be empirically observed and were obtained
by calibration. The approach is described in detail elsewhere
(Whyte et al, 2011). Briefly, the model was fitted to data on
colorectal cancer incidence (by stage) and mortality in Ireland
(from the National Cancer Registry and death registrations), and
the likely prevalence of adenomas and undiagnosed cancers
(estimated from Alexander and Weller, 2003 and Pendergrass
et al, 2008). Parameters were estimated using Markov Chain Monte
Carlo (MCMC) methods and the Metropolis-Hastings algorithm,
using a normal likelihood function for observations about
mortality, incidence, and prevalence and non-informative
Beta(1,1) priors. The model was run using three independent
chains with a burn-in of 2000 iterations for each. The set of
transition probabilities with the highest likelihood was used in the
base-case analysis (Supplementary Table S1). Supplementary
Figures 1 and 2 compare actual and model-predicted colorectal
cancer incidence and mortality.
Analysis
Costs and health outcomes associated with spending time in
each health state were aggregated over the time horizon to
estimate the total cost and health gain associated with each
screening option.
In the base-case analysis, costs and health outcomes were
discounted at 4% per annum (as recommended for evaluations of
health technologies in Ireland; http://www.hiqa.ie) starting at age
55. The marginal cost-effectiveness of each screening scenario
compared with the status quo (i.e. a policy of no screening) was
assessed using incremental cost-effectiveness ratios (ICERs).
Scenarios that were not dominated were compared. Although
there is no formal cost-effectiveness threshold in Ireland, the HSE
have reimbursed most interventions with an ICER oh45 000 per
QALY gained.
Selected model parameters were varied in one-way sensitivity
analyses. Key parameters varied included those where there is
debate (e.g. discount rate; Claxton et al, 2011) and/or particular
uncertainty (e.g. screening uptake). Probabilistic sensitivity
analysis (PSA) was undertaken using Monte Carlo simulation to
sample simultaneously from all uncertain model parameters
(Table 1). This joint uncertainty was propagated through the
model over 1200 iterations (which was sufficient for convergence)
to estimate the probability that each screening option was optimal.
Natural history parameters were sampled from the parameter sets
obtained through calibration, incorporating correlation between
these parameters. Most other parameters were treated as
independent, but a few which were considered inter-dependent
(e.g. test sensitivities for adenomas and cancers) were assigned
perfectly correlated distributions.
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Table 1 Parameter estimates, with base-case values, ranges and distributions
Model parameter Base-case
Range
for SA
Distribution
for PSAa Source
Performance of screening tests
gFOBT sensitivity for adenomas 11% 10–12% Beta
(11.40, 92.10)
Allison et al, 1990; Castiglione et al, 1991;
Foley et al, 1992; Allison et al, 1996;
Brevinge et al, 1997; Lieberman and Weiss, 2001;
Niv et al, 2002; Sung et al, 2003 Collins et al, 2005
gFOBT sensitivity for CRC 36% 31–42% Beta
(105.00, 186.60)
gFOBT specificity for adenomas and CRC 97% 96–98% Beta
(1083.40, 33.50)
FIT sensitivity for adenomas 21% 19–22% Beta
(594.62, 2236.92)
Allison et al, 1996; Itoh et al, 1996; Chen et al, 1997;
Nakama et al, 2000; Nakama et al, 2001;
Cheng et al, 2002; Gondal et al, 2003; Liu et al, 2003;
Morikawa et al, 2005; Nakazato et al, 2006;
Allison et al, 2007; Morikawa et al, 2007
FIT sensitivity for CRC 71% 67–75% Beta
(35.29, 143.08)
FIT specificity for adenomas and CRC 95% 94–96% Beta
(1732.57, 91.19)
FSIG sensitivity for low-risk distal adenomas 65% 60–70% Beta
(235.00, 126.54)
Expert opinion informed by Rozen et al, 1987;
Lieberman and Weiss, 2001; Sung et al, 2003
FSIG sensitivity for intermediate/high-risk distal adenomas 74% 68–78% Beta
(180.00, 63.24)
FSIG sensitivity for distal CRC 90% 85–95% Beta
(90.00, 10.00)
FSIG specificity for distal adenomas and CRC 92% 90–95% Beta
(250.00, 21.74)
Uptake and compliance with screening and diagnostic tests
gFOBT uptake 53% 32–70% Uniform
(32%, 70%)
Weller et al, 2006; Information Services Division, 2008
FIT uptake 53% 32–70% Uniform
(32%, 70%)
FSIG uptake 39% 24–67% Uniform
(24%, 67%)
UK Flexible Sigmoidoscopy Screening
Trial Investigators, 2002
% of individuals who never accept an offer of screeningb 13% 0–41% — Weller et al, 2006
COL compliance (diagnostic test) 86% 81–90% Uniform
(81%, 90%)
Weller et al, 2006; Information
Services Division, 2008
Performance of diagnostic tests and related parameters
COL sensitivity for low-risk adenomas 77% 73–80% Beta
(350.00, 104.55)
van Rijn et al, 2006 Bressler et al, 2007
COL sensitivity for intermediate/high-risk adenomas 98% 93–99% Uniform
(93%, 99%)
COL sensitivity for CRC 98% 95%–99% Uniform
(95, 99%)
COL specificity for adenomas and CRC 97% 96–98% Beta
(970.00, 30.00)
Expert opinion
CTC sensitivity for low-risk adenomas 53% 45–60% Beta
(80.00, 70.94)
Expert opinion, informed by Cotton et al, 2004; Halligan
et al, 2005; Mulhall et al, 2005; Johnson et al, 2008
CTC sensitivity for intermediate/high-risk adenomas 85% 48–100% Beta
(4.50, 0.79)
CTC sensitivity for CRC 85% 75–95% Beta
(50.00, 8.82)
CTC specificity for adenomas and CRC 86% 80–90% Beta
(140.00, 22.79)
Average number of adenomas removed per person 1.9 — — Winawer et al, 1993
Surveillance of screening-detected adenomas
% of those in with intermediate/high-risk adenomas
removed in whom the adenoma was high-risk
29% — — Alexander and Weller, 2003; Weller et al, 2006
COL compliance (surveillance) 86% 81–90% Uniform
(81%, 90%)
Assumption based on Weller et al, 2006;
Information Services Division, 2008
Harms of screening
FSIG probability of perforation (with or without
polypectomy)
0.002% 0–0.051% Uniform
(0%, 0.051%)
UK Flexible Sigmoidoscopy Screening
Trial Investigators, 2002
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Table 1 (Continued )
Model parameter Base-case
Range
for SA
Distribution
for PSAa Source
FSIG probability of death following perforation 6.452% 0–9.070% Uniform
(0%, 9.070%)
Gatto et al (2003)
Probability of (major) bleeding following FSIG 0.029% 0.002–0.054% Uniform
(0.002%, 0.054%)
UK Flexible Sigmoidoscopy Screening
Trial Investigators, 2002
COL probability of perforation (with polypectomy) 0.216% 0.168–0.298% Uniform
(0.168%, 0.298%)
Dafnis et al, 2001
COL probability of perforation (without polypectomy) 0.107% 0.010–0.249% Uniform
(0.010%, 0.249%)
COL probability of death following perforation 5.195% 0–9.070% Uniform
(0%, 9.070%)
Gatto et al (2003)
Probability of (major) bleeding following COL 0.379% 0.065–0.412% Uniform
(0.065%, 0.412%)
UK Flexible Sigmoidoscopy Screening
Trial Investigators, 2002
Health-related QoL
Utility: cancer free 0.94 — — Fryback and Lawrence (1997)
Utility: stage I, II, III, IV cancer 0.80 0.43–0.94 0.94*Beta
(3.92, 0.69)
Ramsey et al (2000)
Costs
gFOBT kitc h1.70 h1.36–h2.04 Uniform
(h1.36, h2.04)
Estimated by authors
gFOBT processing/analysisd h7.81 h6.25–h9.37 Uniform
(h6.25, h9.37)
FIT kitc h3.75 h3–h4.50 Uniform
(h3, h4.50)
FIT processing/analysisd h11.60 h9.28–h13.92 Uniform
(h9.28, h13.92)
Cost of FSIG (with/without polypectomy) h150 h120–h180 Uniform
(h120, h180)
Whynes et al, 2003; VHI Healthcare
Cost of COL h650 h520–h780 Uniform
(h520, h780)
HSE Casemix Unit, 2008
Cost of CTC h550 h440–h660 Uniform
(h440, h660)
Expert opinion
Cost of treating bowel perforation h10 200 h8160–h12 240 Uniform
(h8160, h12 240)
HSE Casemix Unit, 2008
Cost of admittance for bleeding h3079 h2463–h3695 Uniform
(h2463, h3695)
Pathology cost for adenoma h65 h52–h78 Uniform
(h52, h78)
Tappenden et al, 2004
Pathology cost for cancer h530 h424–h636 Uniform
(h424, h636)
Lifetime cost stage I CRC-symptomatic h23 688 h18 950–h28 425 Uniform
(h18 950, h28 425)
Tilson et al, 2011
Lifetime cost stage II CRC-symptomatic h37 180 h29 744–h44 616 Uniform
(h29 744, h44 616)
Lifetime cost stage III CRC-symptomatic h48 835 h39 068–h58 602 Uniform
(h39 068, h58 602)
Lifetime cost stage IV CRC-symptomatic h36 602 h29 281–h43 922 Uniform
(h29 281, h43 922)
Lifetime cost stage I CRC-screen-detected h22 885 h18 308–h27 462 Uniform
(h18 308, h27 462)
Lifetime cost stage II CRC-screen-detected h36 377 h29 102–h43 652 Uniform
(h29 102, h43 652)
Lifetime cost stage III CRC-screen-detected h48 032 h38 426–h57 638 Uniform
(h38 426, h57 638)
Lifetime cost stage IV CRC-screen-detected h35 799 h28 639–h42 959 Uniform
(h28 639, h42 959)
Discount rate
Discount rate for costs and benefits 4% 0–6% — Recommended for Ireland
Abbreviations: COL¼ colonoscopy; CRC¼ colorectal cancer; CTC¼CT colonography; FIT¼ faecal immunochemical test; FSIG¼ flexible sigmoidoscopy; gFOBT¼ guaiac-
based faecal occult blood test; PSA¼ probabilistic sensitivity analysis; SA¼ sensitivity analysis; low-risk adenoma(s),o10mm; intermediate/high-risk adenoma(s),X10mm. aif no
distribution given, parameter was not varied in the PSA. brelevant to gFOBT and FIT scenarios only. ccost per kit dispatched (i.e., cost per individual invited to participate in
screening). dcost per kit completed and returned (i.e., cost per screening participant).
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RESULTS
Base-case analysis: core-screening scenarios
No screening was the least expensive option. In the base-case
analysis, once-only FSIG at age 60 was expected to be associated
with the smallest marginal cost over the lifetime of the cohort
compared with no screening (h3.43 per person); this was followed
by biennial gFOBT at age 55–74 (h33.63 per person), and biennial
FIT at age 55–74 (h40.17 per person; Table 2). The cost of
screening (including test kits/examinations, diagnostic procedures,
perforations and bleeds, and adenoma surveillance) was similar for
gFOBT and FSIG (h56 and h61 per person, respectively), and more
than three times higher for FIT (h222 per person).
Compared with no screening, over the lifetime of the cohort all
three screening scenarios were associated with a gain in QALYs,
which was greatest for FIT (Table 2). All three scenarios appeared
to have favourable cost-effectiveness profiles when compared
marginally against no screening (i.e. the ICER was significantly
lower than the notional cost-effectiveness threshold of h45 000 per
QALY). The lowest ICER vs no screening was for once only FSIG at
age 60 (h589 per QALY gained), followed by FIT at age 55–74
(h1696 per QALY gained) and gFOBT at age 55–74 (h4428 per
QALY gained). gFOBT was eliminated by extended dominance: it
was more costly than FSIG and less effective than FIT. The ICER
for FIT at age 55–74 vs once-only FSIG at age 60 was h2058 per
QALY, which would be considered favourable.
Over the lifetime of the cohort, compared with no screening, all
three scenarios would result in a modest fall in colorectal cancer
incidence and a larger fall in colorectal cancer mortality (Table 3).
These decreases were expected to be greatest for FIT-based
screening (15% fall in incidence, 36% fall in mortality). Faecal
immunochemical testing would also result in the largest percen-
tage of screen-detected cases (30%), and smallest percentage of
symptomatic cases (68%), in the population (Table 3). All three
screening scenarios have the potential to change the stage
distribution of cancers in the population, such that a greater
proportion would be diagnosed at an early stage. With no
screening, the model predicted that 12% of cancers would be
stage I at diagnosis, 25% stage II, 35% stage III, and 29% stage IV.
With FIT-based screening, 79% of screen-detected and 42% of
symptomatic cancers were predicted to be stage I or II; the
comparable figures for gFOBT-based screening were 73 and 39%,
and for FSIG screening were 71 and 37%.
The FSIG-based screening would result in a higher lifetime rate
of endoscopy procedures than screening based on faecal testing,
but most of these would be FSIG screening examinations (Table 4).
The rate of colonoscopies over the lifetime of the cohort would
be ten times higher (34 632 vs 3386 per 100 000), and that of
polypectomies eight times higher (9486 vs 1125 per 100 000), for
Table 2 ICER, based on QALYs per person, for corea and age-variant screening scenarios
Scenario
Cost of screening and CRC
management per personb
Incremental costs
per personc
Expected QALYs
per person
Incremental QALYs
per personc
ICER-Incremental cost
per QALY gained
No screening h 1074 — 10.961 — —
gFOBT at 55–74 years h 1107 h 33.63 10.968 0.0076 h 4428d,e
gFOBT at 55–64 years h 1092 h 18.35 10.966 0.0051 h 3613e
gFOBT at 65–74 years h 1089 h 15.66 10.963 0.0026 h 5919e
FIT at 55–74 years h 1114 h 40.17 10.984 0.0237 h 1696
FIT at 55–64 years h 1094 h 20.06 10.978 0.0175 h 1153
FIT at 65–74 years h 1088 h 13.94 10.969 0.0082 h 1698e
FSIG once at 60 years h 1077 h 3.43 10.966 0.0058 h 589
FSIG once at 55 years h 1092 h 18.19 10.968 0.0069 h 2659e
Abbreviations: FIT¼ faecal immunochemical test; FSIG¼ flexible sigmoidoscopy; gFOBT¼ guaiac-based faecal occult blood test; ICER¼ incremental cost-effectiveness ratios;
QALYs¼ quality-adjusted life-years. Costs and outcomes discounted at 4%. aCore screening scenarios are shaded. bIncludes costs of screening (including faecal testing kit and
processing or FSIG examination, diagnostic colonoscopy/CT colonography, pathology, perforations and bleeds, adenoma surveillance) and diagnosis, treatment and follow-up of
screen-detected cancers. Costs of CRC management are a weighted average of costs of managing screen-detected and symptomatic CRC. cEach incremental value compares
values for that strategy with common baseline of no screening. dIn comparison of core scenarios, strategy considered dominated by combination of FIT at 55–74 years and FSIG
once at 60 years. eIn comparison of all strategies, strategy considered dominated by FSIG at age 60, FIT at age 55–74, FIT at age 55–64 or combinations of these.
Table 3 Lifetime ratesa of colorectal cancer incidence and mortality per 100 000 population, percentage of cases which would be detected by screening,
surveillance and symptomatically, and percentage reductions in incidence and mortality compared with no screening, for core screening scenarios
Incidence
Screen
detected
CRC
Surveillance-
detected
CRCb
Symptomatic
CRC Mortality
Scenario Rate
% of
cases Rate
% of
cases Rate
% of
cases
% reduction in
CRC incidencec
CRC mortality
rate
% reduction in
CRC mortalityc
No screening 0 — 0 — 5158 100 — 2287 —
gFOBT at 55–74 years 695 13.6 11 0.2 4401 86.2 1.0 2016 11.8
FIT at 55–74 years 1313 29.8 78 1.8 3010 68.4 14.7 1465 36.0
FSIG once at 60 years 138 2.8 25 0.5 4742 96.7 4.9 2116 7.5
Abbreviations: CRC¼ colorectal cancer; FIT¼ faecal immunochemical test; FSIG¼ flexible sigmoidoscopy; gFOBT¼ guaiac-based faecal occult blood test. aOver the entire
lifetime of the cohort, therefore, for gFOBT and FIT includes 10 screening rounds. bCRC detected at surveillance among those with intermediate/high-risk adenomas found at
screening. cEach incremental value compares values for that strategy with common baseline of no screening.
Cost-effectiveness of colorectal cancer screening
L Sharp et al
810
British Journal of Cancer (2012) 106(5), 805 – 816 & 2012 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
FIT-based screening than for screening based on gFOBT. A
consequence of this would be a higher rate of complications with
FIT-based screening than the other options (Table 4).
Sensitivity analyses
When costs and benefits were not discounted, all three screening
scenarios appeared more cost-effective. The ICERs compared with
no screening were: FIT at age 55–74, -h1399 per QALY gained;
gFOBT at age 55–74, h410 per QALY gained; and FSIG at age 60,
h2012 per QALY gained.
Figure 2 shows the results of the one-way sensitivity analysis for
FIT. In addition to discount rate, the most influential parameters
were costs of screening tests and costs of managing colorectal
cancer. However, even when these were varied, the ICER for FIT vs
no screening remained very much below the notional cost-
effectiveness threshold, and in some instances became cost saving
(ICERo0). Varying screening uptake had very little impact on
cost-effectiveness. The results of the one-way sensitivity analyses
for FSIG and gFOBT were similar to those for FIT (i.e., the same
parameters had the greatest impact, and in all instances, the ICERs
for screening vs no screening remained very much below the
notional cost-effectiveness threshold (data not shown)).
Figure 3 shows the results of the PSA. In only a handful of
simulations, all pertaining to gFOBT, screening was expected to
result in a loss of QALYs compared with no screening. Uncertainty
was greatest for FIT, but the outlying simulations remained well
below the notional cost-effectiveness threshold. In almost every
instance, the incremental costs of screening with gFOBT exceeded
those for FSIG, whereas the incremental QALYs for FIT exceeded
those for the other two scenarios. Thus, the findings from the base-
case analysis were confirmed i.e., (1) all three scenarios were
almost always likely to be considered highly cost-effective
compared with no screening; and (2) screening with FIT was
likely to result in the greatest health gain and would, therefore, be
considered the optimal strategy.
Age-variant scenarios
The cost-effectiveness results of the base-case analyses for the five
age-variant scenarios are shown in Table 2. All variant scenarios
Table 4 Lifetime ratesa per 100 000 population of screening-related endoscopic proceduresb, and associated complicationsc, for the core screening
scenarios
Endoscopic procedures Complications
Scenario
Flexible
sigmoidoscopy Colonoscopy Polypectomy
Major
bleedingd
Bowel
perforation
Deaths due to
perforation
gFOBT at 55–74 years — 3386 1215 12 5 0.26
FIT at 55–74 years — 34 632 9486 132 57 3.00
FSIG once at 60 years 40 177 2543 2487 22 5 0.25
Abbreviations: FIT¼ faecal immunochemical test; FSIG¼ flexible sigmoidoscopy; gFOBT¼ guaiac-based faecal occult blood test. aOver the entire lifetime of the cohort,
therefore, for gFOBT and FIT includes 10 screening rounds. bRelated to screening, diagnosis, or surveillance. cComplications associated with diagnostic and surveillance
colonoscopy and, where relevant, FSIG. dMajor abdominal bleeding, requiring admission or intervention.
–   2,000
FIT sensitivity
COL sensitivity
Proportion who never participate
in screening
FIT uptake
COL compliance
Utility
Cost of FIT
Cost of COL
Life time costs of treating CRC
Discount rate
Incremental costs per QALY (ICER)
Base-case ICER   1,696 per QALY gained
5,0004,0003,0002,0001,0000–  1,000
Figure 2 Incremental costs per QALY compared with no screening, when selected parameters were varied independently, for biennial FIT at
55–74 years. Abbreviations: COL¼ colonoscopy; CRC¼ colorectal cancer; FIT¼ faecal immunochemical test.
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Figure 3 PSA: incremental costs and incremental QALYs with 95%
confidence ellipses, for core screening scenarios compared with
no screening. Abbreviations: FIT¼ faecal immunochemical test; FSIG¼
flexible sigmoidoscopy; gFOBT¼ guaiac-based faecal occult blood test.
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had favourable cost-effectiveness profiles compared with no
screening. For faecal testing, the ICER vs no screening was lower
for screening restricted to the younger (55–64 years), compared
with the full (55–74) age group. The FIT-based scenarios were
more cost-effective, vs no screening, than the gFOBT scenarios. For
FSIG, offering screening at 55 years was less cost-effective than at
age 60. The only strategies not eliminated by extended dominance
were, in order of incremental QALYs gained: FSIG at age 60, FIT at
55–64 years, and FIT at 55–74 years. The ICER for FIT at 55–64
years vs FSIG at 60 years was h1436 per QALY gained. The ICER
for FIT at 55–74 years compared with FIT at 55–64 years was h3221
per QALY gained, indicating that FIT in the full age group (55–74
years) remained the most cost-effective strategy. This was confirmed
in PSA (Data not shown). The cost-effectiveness acceptability curve
(Data not shown) showed that if decision makers were willing to
pay a maximum of around h1000 per additional QALY, the most
cost-effective strategy would be expected to be FSIG at age 60. At a
threshold of Xh4000 per additional QALY, the optimal option
would be biennial FIT at 55–74 years (at h4000, P¼ 0.693 that this
is the most cost-effective strategy; at h6000, P¼ 0.907; at h8000,
P¼ 0.961, at h14 000, P¼ 0.990).
DISCUSSION
The key issues in deciding whether to introduce a new screening
programme include whether: (1) screening represents a cost-
effective intervention (i.e., the health gains are likely to be
significant compared with the costs involved); (2) uptake is
likely to be sufficiently high for screening to be effective; and
(3) implementation is feasible (i.e., sufficient health service
resources are available to diagnose, treat and follow-up those
found to have adenomas and cancer).
Cost-effectiveness
This analysis clearly shows that a population-based colorectal
cancer screening programme in Ireland – using gFOBT, FIT, or
FSIG – would be likely to be considered highly cost-effective
compared with no screening. This is generally consistent with the
conclusions from most previous cost-effectiveness evaluations
(HIQA, 2009; and references therein; Berchi et al, 2010; Lejeune
et al, 2010; Telford et al, 2010; Hassan et al, 2011; van Rossum
et al, 2011). Estimates from individuals studies are not entirely
comparable, not least because the screening scenarios evaluated,
and the outcomes and comparators, differ. Nonetheless, the ICERs
in the current study were generally somewhat lower than to those
reported elsewhere. For example, in a French study, the ICER for
biennial FIT was h8589 per life year saved (Hassan et al, 2011)
compared with h1696 per QALY gained in this analysis. These
differences are probably because of the rising costs of colorectal
cancer treatment (Schrag, 2004). We included costs of combination
chemotherapies and monoclonal antibodies, which are expensive,
but now part of standard care, and our estimated treatment costs
were higher than those reported in older studies from other
European countries (Tilson et al, 2011). One consequence of the
rising treatment costs is that screening could be considered
desirable not only in terms of reducing colorectal cancer incidence
and mortality, but also as a means to control treatment costs
(Lansdorp-Vogelaar et al, 2009).
In this analysis, biennial FIT at 55–74 years dominated biennial
gFOBT for the same age range, findings similar to van Rossum
et al (2011), whose analysis was based on empirical RCT data.
Importantly, in light of recent evidence that FSIG is effective in
reducing cancer incidence and mortality (Atkin et al, 2010; Segnan
et al, 2011), we found that once-only FSIG had the lowest ICER
compared with no screening. However, FIT was associated with
much larger health gains and, on this basis, would be considered
the optimal option.
Uptake
Previous cost-effectiveness analyses of colorectal cancer screening
have been criticised for including overly optimistic estimates of
screening uptake and compliance with diagnostic investigations,
leading to uncertainty in the true cost-effectiveness of screening
(van Rossum et al, 2011). The estimates of participation in the
current study were chosen because they were considered to be
plausible (53% for faecal tests based on the UK pilot programmes
and 39% for FSIG based on the UK trial) (UK Flexible
Sigmoidoscopy Screening Trial Investigators, 2002; Weller et al,
2006; Information Services Division, 2008). In addition, we
assumed that uptake would be the same for FIT and gFOBT
because, although some studies have suggested that uptake could
be higher with FIT than gFOBT (Cole and Young, 2001; Deutekom
et al, 2010; Hol et al, 2010), this is not a universal finding (Levi
et al, 2011). We varied uptake in sensitivity analyses and the
relative cost-effectiveness of screening changed little; this is
because, as well as reducing costs, lower uptake also reduces
effectiveness. For example, with 70% FIT uptake the ICER was
h1771 per QALY gained compared with h1696 in the base-case.
Thus, had we assumed that FIT uptake exceeded that for gFOBT,
our main conclusions would have been unchanged.
Although they do not impact greatly on cost-effectiveness, high
uptake rates are essential if screening is to be effective in reducing
mortality in the population. Whether the participation levels from
the analysis are achievable in Ireland is unclear. On one hand, the
base-case estimates were higher than uptake in some Europe
programmes (Peris et al, 2007; Kis, 2010; Zorzi et al, 2010). On the
other hand, 51% of 9993 individuals aged 50–74 years resident in
Dublin and invited to complete a FIT did so (McNamara et al,
2011), suggesting the FIT uptake level considered in our analysis is
realistic and attainable.
Screening programmes also require high levels of compliance
with diagnostic tests and surveillance following polypectomy. Our
base-case estimate for colonoscopy compliance was derived
primarily from the UK screening programmes and very close to
the level reported in the Dublin study (McNamara et al, 2011).
However, most data relates to diagnostic colonoscopy and
compliance with surveillance remains uncertain. Although (as
our analysis shows) low compliance with surveillance would
have a relatively modest influence on cost-effectiveness, it would
adversely impact on programme effectiveness.
Feasibility
Cost-effectiveness should not be considered in isolation to issues
relating to service delivery, and although FIT in age 55–74 years
was considered the optimal option, such a programme would
require substantial more resources for colonoscopy (and CT
colonography and other diagnostic procedures) than one based on
gFOBT or FSIG. An option appraisal in England, based on a similar
economic model to the current analysis, recognised the importance
of endoscopy resource and capacity issues, and suggested that
gFOBT-based, although less cost-effective, was probably more
feasible than a programme based on FSIG (FIT was outwith the
scope of the analysis; Tappenden et al, 2004). In the UK pilot
programmes, which are likely to be much less resource intensive
than a programme based on FIT, achieving sufficient colonoscopy
capacity has been a major challenge, and has underpinned the age
and area-based rollout. Hence, any programme that adopts
primary screening by FIT will have to consider very carefully
how to deliver sufficient capacity for diagnosis and surveillance.
One option to address capacity issues would be to consider
restricting screening to a narrower age range. We found that
screening at 55–64 years had a lower ICER than screening over
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55–74 years, although the gain in QALYs was not as large. Age-
restricted FIT-based screening could be an attractive strategy
therefore, not only for Ireland but also elsewhere. Of course, this is
only one of a range of possible implementation options; others
might include rollout area by area or across age groups until the
full country/age range is incorporated or setting a high FIT cut-off
level for colonoscopy referral. In Ireland, on the basis of the cost-
effectiveness results reported here, a decision was taken to
implement a FIT-based colorectal cancer screening programme
from 2012; in the short-term, a restricted age range (60–69 years)
will be invited to participate but the stated intention is to
eventually include the entire 55–74 years age group (National
Cancer Screening Service, 2011).
A related issue concerns adverse effects of endoscopy among
screening participants. Because of the high rate of colono-
scopies and polypectomies, screening based on FIT would be
associated with a much higher lifetime risk of major abdominal
bleeding, bowel perforation, and death than screening with
gFOBT or FSIG. However, even with FIT-based screening the
absolute risk to an individual of experiencing one of these
complications is low, and in ongoing programmes major compli-
cations of colonoscopy are rare (Regula et al, 2006; Information
Services Division, 2008)
FIT vs gFOBT
The FIT is increasingly being adopted as a primary test in
screening programmes. As this strategy was more cost-effective
than screening by gFOBT with reflex FIT (currently implemented
in Scotland) this raises the question of whether the UK screening
programmes should use primary FIT testing. Dealing with
advances in the evidence base is always a challenge for existing
screening programmes. The efficacy of gFOBT in reducing
colorectal cancer mortality is established (Hewitson et al, 2007)
but FIT may (or may not) be more sensitive and more cost-
effective. We derived our estimates of the performance character-
istics of gFOBT from diagnostic cohort studies of Hemoccult and
Hemoccult II. Other, newer, gFOBTs may have a higher sensitivity
(van Dam et al, 2010) and the potential to be more effective. We
repeated our analysis using higher estimates of gFOBT sensitivity
obtained from a study using Hemoccult Sensa (adenomas, 20%,
cancers, 64%; Allison et al 2007). The ICER compared with no
screening was h1701 per QALY gained – very close to that for
screening using FIT (h1696 per QALY gained). Therefore, it is
entirely possible that a screening programme based on gFOBT
could achieve similar health gains to one based on FIT, if a
sufficiently sensitive test was used.
Comparisons with results of RCTs
Our estimate of the mortality reduction achieved with gFOBT-
based screening (12%) was slightly lower than RCT results (16%;
Hewitson et al, 2007). Our estimate of the effect of FSIG screening
on colorectal cancer incidence (5% reduction) was higher than in
one trial (Hoff et al, 2009), but lower than in others (Atkin et al,
2010; Segnan et al, 2011). There are numerous reasons why
findings from RCTs and cost-effectiveness analyses might not
entirely correspond, including significant differences between the:
trial participants and population eligible for screening in Ireland;
time horizons; diagnostic and surveillance protocols; and values of
key parameters (e.g. test sensitivity, and uptake).
Strengths and limitations
Unlike most previous natural history models, we assumed that
some cancers (14%) would arise without a prior adenoma.
However, the frequency and malignant potential of hyperplastic
and flat polyps in European populations is uncertain. Thus, if
486% of cancers develop though the adenoma-carcinoma
sequence, our model is likely to have underestimated screening
effectiveness, with the extent of underestimation differing for
faecal and endoscopic tests.
Important questions remain about the efficacy and effectiveness
of the screening and diagnostic tests considered here. Even for
gFOBT, which has been extensively investigated, there remains a
lack of certainty about true performance characteristics, particu-
larly for the newer versions of the test. The estimation of sensitivity
and specificity of FIT in population-based screening is hampered
by the fact that numerous tests are available with heterogeneous
performance characteristics, and various approaches have been
taken to estimate sensitivity, a criticism that has been made
previously (Burch et al, 2007). In addition, although quantitative
FITs, theoretically, allow the level to define a ‘positive’ result to be
set for individual populations and in accordance with local
circumstances (e.g. to suit available colonoscopy capacity;
Fraser et al, 2008) the absence of high-quality data available at
the time we parameterised the models meant that we did not
estimate cost-effectiveness of different cut-offs. In effect, we
assessed cost-effectiveness at 100 ngml1 as this was the cut-off
in the key quantitative studies which informed the parameter
estimates. A recent analysis suggests that FIT may be even more
cost-effective at a cut-off of 50 ngml1 than at 100 ngml1
(Wilschut et al, 2011). In addition, some recent studies suggest
that sensitivity of FIT might exceed the values used in the analysis,
particularly at low cut-offs (see, for example, Omata et al, 2011;
Rozen et al, 2011). The impact of higher sensitivity on cost-
effectiveness is twofold – it increases the number of lesions
detected and increases costs. Therefore, as test sensitivity is
not a major driver of cost-effectiveness, if we were to repeat our
analysis based on these newer studies, it is likely that our overall
conclusions would be unchanged.
As regards FSIG, there are few studies of sensitivity and
specificity, and the gold standard (colonoscopy) misses lesions
(van Rijn et al, 2006; Bressler et al, 2007). This means that such
studies will tend to overestimate FSIG performance. Moreover,
colonoscopy performance characteristics are uncertain because it
is usually considered the gold standard for endoscopic evaluation.
In light of this uncertainty, it was reassuring that our overall
conclusions were unchanged after extensive sensitivity analyses.
However, it should be noted that the ranges for the parameter
values used in the sensitivity analyses were sometimes informed by
expert opinion because robust data was lacking.
We chose to evaluate a strategy that combined gFOBT with reflex
FIT, instead of the more conventional approach of reflex gFOBT. This
was because second-line FIT has been shown to limit the number of
colposcopy referrals (Fraser et al, 2006, 2007). However, we accept
that the strategy is not widely used. Our analyses were based on
QALYs and the model incorporated quality-of-life decrements
associated with colorectal cancer. It is entirely possible that screening
might also impact adversely on quality-of-life (e.g., in those with a
positive screening test or those undergoing annual surveillance), but
we were unable to identify any robust utility data for these health
states. Thus, our study (and other similar studies) may somewhat
overestimate benefits of screening. In common with similar analyses,
we did not include costs of setting up programme infrastructure and
some costs associated with ongoing programme administration and
delivery. Many of these depend on the business model adopted.
Because of the limited evidence base, costs incurred by screening
participants (such as travel costs) and societal costs (such as lost
productivity) were not included. This would tend to mean that our
cost estimates are conservative. It is important, however, to
acknowledge that all of these costs exist and are likely to vary for
different screening modalities.
A major area of uncertainty in this and other similar models
relates to the true underlying population prevalence of adenomas.
We estimated prevalence on the basis of data from a recent, large,
well-conducted, autopsy study and the first round of the pilot
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screening programmes in Scotland and England (Alexander
and Weller, 2003; Pendergrass et al, 2008). Our estimates of
prevalence were lower than those from older autopsy series, which
other analyses have used. The prevalence estimates from these
older studies vary greatly (Tappenden et al, 2004) and they have
been criticised for being small, providing little information on
the source population, and not always clearly distinguishing
between different types of polyp (Jass et al, 1992). It is impossible
to be sure which of the available sources is closer to the true
prevalence of adenomas.
Finally, although cost-effectiveness analysis is a valuable tool for
comparing costs and benefits of alternative screening options, it
may not fully address ‘real world’ issues around programme
implementation and delivery. For example, such analyses do not
provide annual estimates of health service resource requirements
for the actual population eligible for screening. Alternative
approaches to running economic models can be used to obtain
this type of information (see, for example, Health Information and
Quality Authority, 2009).
CONCLUSIONS
This analysis suggests that a screening programme based on
biennial screening at 55–74 years with FIT would be preferable to
one based on biennial gFOBT (with reflex FIT) at 55–74 years or
once-only FSIG at 60 years. Although a programme based on FIT is
expected to result in the greatest health improvement, it would
require more colonoscopy resources and result in more individuals
suffering adverse effects. The major challenges for policy makers
are, therefore, balancing the benefits and harms of screening while
ensuring sufficient capacity for follow-up of screen-detected
adenomas and cancers.
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